Login to Your Account

Santaris Getting $10M Up Front in BMS Drug Discovery Pact

By Cormac Sheridan
Staff Writer

Wednesday, April 17, 2013

Santaris Pharma A/S is getting $10 million up front and could earn up to $90 million more in per-product milestones from a multiproduct drug discovery alliance with Bristol-Myers Squibb Co., based on its Locked Nucleic Acid (LNA) antisense technology.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription